CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

EDAP TMS

EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...

Stratus Medical

Advancing RF Technology for the treatment of chronic pain. Nimbus provides a large volume lesion that is cost effective and easy to use.

PAR Pharmaceuticals

PAR Pharmaceuticals is a Woodcliff Lake, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transcend Orthotics & Prosthetics

Transcend orthotists and prosthetists are fully certified and experienced in serving the needs of our patients.

SourceMark

A certified minority-owned business, SourceMark continues to focus on your needs to improve the lives of all patients, customers, and healthcare providers. Our clinical advisory groups are personally involved with the continued improvement of current p...